CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, SIRT1 inhibition had less of an effect on proliferation and apoptosis of normal CD34+ cells, suggesting that SIRT1 might be a new target for eliminating CML cancer stem cells.